ONCOLOGY Vol 40, Issue 7

Experts discussed identifying high-risk cutaneous squamous cell carcinoma and how cemiplimab data from EMPOWER-CSCC-1 and C-POST inform multidisciplinary care.

A pilot early phase 1 trial (NCT07261657) represents the first clinical effort to activate persisting transferred rare persisting cells by using IL-15 superagonist N-803.

Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access.

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.

Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.